Skip To Main Content
Double-Blind Trial on Muck Rack

Double-Blind Trial

As seen in: Stockwatch
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Double-Blind

Contact Double-Blind, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

|
By Double-Blind Trial
| Stockwatch
Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation Additionally, new data and updates from AbbVie's telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across NSCLC and small cell lung cancer (SCLC) to be shared Research reflects AbbVie's strategy aimed at building a lung cancer pipeline spanning next-generation immunotherapies, targeted antibody-drug conjugates...
Open in Who Shared View Duplicates (88) Issue with article?

Microbiome, Diet, Health, and Disease: Policy Needs to Move Forward

|
By Yolanda Sanz, Manfred Ruthsatz, , Kathleen D'Hondt, Such As MyNewGut, L. S. and Marchesi, Double-Blind Trial, C. A. and Carvalho, OECD Publishing, G. R. and Roberfroid, J. B. and O'Keefe, van Hylckama Vlieg
| Regulatory Affairs Professionals Society
This article covers policy needs concerning the rapidly evolving field of microbiome and diets with respect to health and disease.
Open in Who Shared Issue with article?
See all 2 articles